Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit
Ilya S. Senatorov(National Cancer Institute), Kathleen Kelly(National Cancer Institute), Michael L. Beshiri(National Cancer Institute), Eva Corey(University of Washington), Keith H. Jansson(National Cancer Institute), Morgan Riba(National Cancer Institute), Ross Lake(National Cancer Institute), Sonam Raj(National Cancer Institute), Joel M. Bowman(Atlanta University Center), Yasmine C. Abbey(National Cancer Institute), Brian J. Capaldo(University of Virginia), Aian Neil Alilin(National Cancer Institute), Xiaohu Zhang(National Institutes of Health), Crystal McKnight(National Institutes of Health), Holly M. Nguyen(University of Washington), Paul Shinn(National Institutes of Health), Craig J. Thomas(National Institutes of Health)
Cited by 5
Related Papers
Increased demand for NAD+ relative to ATP drives aerobic glycolysis
|Molecular Cell|2020|561
PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
|Cancer Discovery|2017|336
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|314
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
|Nature Communications|2014|269